Abstract
The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02)
Volume: 14 Issue: 1
Author(s): Ramanaiah Illuri, Bharathi Bethapudi, Senthilkumar Anandakumar, Sasikumar Murugan, Joshua A. Joseph, Deepak Mundkinajeddu, Amit Agarwal and Chandrasekaran C.V.
Affiliation:
Keywords: Anti-inflammatory, Curcuma longa, NR-INF-02, Polysaccharide fraction.
Abstract: The aim of the study was to investigate the safety and anti-inflammatory effects of polysaccharide fraction (F1) of Curcuma longa extract (NR-INF-02) in classical rodent models of inflammation. F1 was evaluated for its acute oral toxicity and found to be safe upto 5000 mg/kg body weight in rats. The anti-inflammatory activity of F1 was evaluated in acute (carrageenan - induced paw edema; xylene - induced ear edema) and chronic (cotton pellet - induced granuloma) models of inflammation. The results of the study demonstrated that F1 significantly (p ≤ 0.05) inhibited carrageenan-induced paw edema at 1 h and 3 h at doses of 11.25, 22.5 and 45 mg/kg body weight in rats. Also, F1 at doses of 15.75, 31.5 and 63 mg/kg significantly inhibited the xylene induced ear edema in mice. In a chronic model, F1 at 11.25, 22.5 and 45 mg/kg doses produced significant reduction of wet and dry weights of cotton pellets in rats. Overall results indicated that F1 of NR-INF-02 significantly attenuated acute and chronic inflammation in rodent models. This study emphasizes on the importance of Curcuma longa polysaccharide’s role in acute and chronic inflammation.
Export Options
About this article
Cite this article as:
Illuri Ramanaiah, Bethapudi Bharathi, Anandakumar Senthilkumar, Murugan Sasikumar, Joseph A. Joshua, Mundkinajeddu Deepak, Agarwal Amit and C.V. Chandrasekaran, Anti-Inflammatory Activity of Polysaccharide Fraction of Curcuma longa Extract (NR-INF-02), Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2015; 14 (1) . https://dx.doi.org/10.2174/1871523014666150407150533
DOI https://dx.doi.org/10.2174/1871523014666150407150533 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Medicinal Applications of Benzimidazoles: An Overview
Current Organic Synthesis Editorial (Thematic Issue: From Nuisance to State-of-the-Art: FDG-PET/CT Imaging of Infection and Inflammation)
Current Molecular Imaging (Discontinued) Lipid Matrix Nanoparticles: Pharmacokinetics and Biopharmaceutics
Current Nanoscience Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability
Current Neuropharmacology Chemistry of Plant Dyes: Applications and Environmental Implications of Dyeing Processes
Current Environmental Engineering Flavones as a Privileged Scaffold in Drug Discovery: Current Developments
Current Organic Synthesis Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Current Medicinal Chemistry The Evil Axis of Obesity, Inflammation and Type-2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry Clinical Pharmacogenetics and Potential Application in Personalized Medicine
Current Drug Metabolism Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry On the Paradigm Shift Towards Multitarget Selective Drug Design
Current Computer-Aided Drug Design Platelets as Potential Immunomodulators: Is There a Role for Platelet Toll-Like Receptors?
Current Immunology Reviews (Discontinued) Biomarkers in the Diagnosis of Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Structure-Based Virtual Ligand Screening: Recent Success Stories
Combinatorial Chemistry & High Throughput Screening Molecular Targets of Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Flavonoids Acting on DNA Topoisomerases: Recent Advances and Future Perspectives in Cancer Therapy
Current Medicinal Chemistry